NSD2-LDD

NSD2-LDD is a ligand-directed degrader (LDD) developed by Bristol Myers Squibb that targets Nuclear receptor binding SET domain protein 2 (NSD2). It utilizes the CRL4-CRBN E3 ubiquitin ligase complex to catalyze the proximity-induced degradation of NSD2. This degradation leads to a global loss of the catalytic product H3K36me2 and a gain of H3K27me3, effectively restoring transcriptional control in t(4;14) multiple myeloma models. Preclinical studies have demonstrated significant tumor volume reduction and survival benefits in xenograft models, highlighting its potential as a therapeutic strategy for multiple myeloma patients with the t(4;14) translocation, which is associated with poor prognosis.

Other names

NSD2 ligand-directed degraderNSD-2 ligand-directed degraderNSD 2 ligand-directed degrader